This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dacou-Voutetakis, C. Articles by Dracopoulou, M. Search for Related Content PubMed PubMed Citation Articles by Dacou-Voutetakis, C. Articles by Dracopoulou, M.

High Incidence of Molecular Defects of the CYP21 Gene in Patients with Premature Adrenarche

Endocrine Unit, Choremis Research Laboratory, A' Pediatric Department, Athens University Medical School, Aghia Sophia Children’s Hospital, Athens 11527, Greece

Address all correspondence and requests for reprints to: Dr. Dacou-Voutetakis, Endocrine Unit, Choremis Research Laboratory, A' Pediatric Department, Athens University Medical School, Aghia Sophia Children’s Hospital, Athens 11527, Greece.

On the basis of hormonal studies, the incidence of defective steroidogenesis in children with premature adrenarche (PA) in the various reports ranges from 0–54%. Molecular studies have not been reported to date. The aim of the present study was to search for defects in the CYP21 gene in children with PA and to detect possible correlations of the molecular defect to pertinent hormonal and clinical data. In 48 children with PA (40 females and 8 males) and without signs of virilization, a Synachten test and molecular studies were carried out. DNA analysis was performed using the Southern blot technique and allele-specific PCR. Synachten (0.25 mg) was given iv, and 17-hydroxyprogesterone and cortisol were determined at 0 and 60 min. At baseline, ⁴-androstenedione, dehydroepiandrosterone sulfate, and 11-deoxycortisol were also determined. Bone age was evaluated using the Greulich and Pyle atlas. Abnormal genotype was detected in 45.8% of the studied subjects; 8.3% were homozygotes, with genotypes concordant with the nonclassical phenotype of 21 hydroxylase deficiency, and 37.5% were heterozygotes for 9 different molecular defects of the CYP21 gene. The children with no detectable molecular defect were designated normal. The 60 min post-Synachten values in homozygotes (17.9 ± 7.1 ng/mL) and heterozygotes (7.1 ± 3.6 ng/mL) were significantly higher than that in normal subjects (3.3 ± 1.5 ng/mL), but with significant overlapping of values. The mean difference between bone age and chronological age differed in the three groups with overlapping values. The basal ⁴-androstenedione level was lower in the normal subjects (0.65 ± 0.3 ng/mL) than in those with abnormal genotype (1.1 ± 0.8 ng/mL). The data indicate that the incidence of molecular defects in PA is quite high. The CYP21 heterozygocity is clinically expressed in some subjects prepubertally. In a significant number of cases the genotype cannot be predicted by the age of onset of PA, the mean difference between bone age and chronological age, or the results of a Synachten test. Follow-up of these children through puberty is imperative and may reveal the clinical significance of the molecular defect, namely more hypertrichosis, intense acne, early puberty, possible abnormal menses, and/or fertility problems in the affected.

This article has been cited by other articles:

				M. I. New Nonclassical 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4205 - 4214. [Abstract] [Full Text] [PDF]

				L. Ibanez, K. K. Ong, N. Mongan, J. Jaaskelainen, M. V. Marcos, I. A. Hughes, F. de Zegher, and D. B. Dunger Androgen Receptor Gene CAG Repeat Polymorphism in the Development of Ovarian Hyperandrogenism J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3333 - 3338. [Abstract] [Full Text] [PDF]

				S. Lajic, S. Clauin, T. Robins, P. Vexiau, H. Blanche, C. Bellanne-Chantelot, and A. Wedell Novel Mutations in CYP21 Detected in Individuals with Hyperandrogenism J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2824 - 2829. [Abstract] [Full Text] [PDF]

				D. P. Merke, S. R. Bornstein, N. A. Avila, and G. P. Chrousos Future Directions in the Study and Management of Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Ann Intern Med, February 19, 2002; 136(4): 320 - 334. [Abstract] [Full Text] [PDF]

				M. Dracopoulou-Vabouli, M. Maniati-Christidi, and C. Dacou-Voutetakis The Spectrum of Molecular Defects of the CYP21 Gene in the Hellenic Population: Variable Concordance between Genotype and Phenotype in the Different Forms of Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2845 - 2848. [Abstract] [Full Text] [PDF]

				Adrenal Hyperandrogenism in Children J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4431 - 4435. [Full Text]